Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
|
PLASMA TREATMENT TO ASYMPTOMATIC PATIENT WITH COVID-19 INFECTION
View current
Revisions
List all revisions
View
Compare to current
3 July 2020 - 10:09pm
by Gladys
24 March 2023 - 6:00am
by Gladys
Changes to
Health condition(s) code
-
+
Coronavirus Infections
+
SARS Virus
+
Coronaviridae Infections
+
Betacoronavirus
+
Severe Acute Respiratory Syndrome
Changes to
Health condition keyword
-
+
COVID-19
Changes to
Intervention code
-
+
Plasma
+
Administration, Intravenous
Changes to
Record Verification Date
-
2020/
07
/
03
+
2020/
08
/
19
Changes to
Next update date
-
2021/
07
/
03
+
2021/
08
/
19
Revision of 24 March 2023 - 6:00am:
PLASMA TREATMENT TO ASYMPTOMATIC PATIENT WITH COVID-19 INFECTION
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
TRANSFUSION WITH CONVALING PLASMA IMMUNIZES THE ASYMPTOMATIC PATIENT WITH COVID INFECTION 19 THAT FOR MORE THAN 30 DAYS IS POSITIVE SARS CoV-2 PCR (COVID-19)
Secondary indentifying numbers:
Not applicable
Issuing authority of the secondary identifying numbers:
Not applicable
Primary sponsor:
Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Ministry of Public Health (MINSAP)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Consuelo
Last name:
Macias Abraham
Medical Specialty :
Specialist 2nd Degree in Immunology
Affiliation:
Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”
Postal address:
Eighth Street No. 460, between 17 and 19, Vedado, Revolution Square
City:
Havana
Country:
Cuba
Zip Code:
10400
Telephone:
+53-78465555
+53-78465554
Email address:
cmabraham@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not applicable
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Recruiting
Date of first enrollment:
05/05/2020
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
COVID-19 infection
Health condition(s) code:
Coronavirus Infections
SARS Virus
Coronaviridae Infections
Betacoronavirus
Severe Acute Respiratory Syndrome
Health condition keyword:
COVID-19
Intervention(s):
Administration of one to four bags (300 ml) of plasma by intravenous route the days 1, 3, 7 and 12.
Intervention code:
Plasma
Administration, Intravenous
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
1. Improvement of the respiratory failure (It will measure as an increase in the partial pressure of oxygen above 60 mmHg or oxygen saturation greater than 90.7%). Measurement time: 48 hours after treatment 2. Clinical improvement (It will measure through the change in the classification from Severe to From Care and From Care to Open Room). Measurement time: 72 hours after treatment 3. Improvement of at least two complete blood count parameters (It will measure as any positive difference in Hemoglobin levels, differential white blood cell count and platelet value). Measurement time: 48 and, 72 hours after treatment 4. Negativization of the PCR (Yes, No). Measurement time: 7 days after the treatment
Key secondary outcomes:
Adverse Events-AE (Occurrence of any AE in the subject (Yes, No), Type of AE (Name of the adverse event), Location (Local, Systemic), Time of onset (Immediate, Late), Duration of AE (Less than a day, Greater than a day), Previous knowledge (Expected, Unexpected), AEs intensity (Mild, Moderate, Severe), AEs severity (Serious, Not serious), AEs result (Recovered, Improved, Persists, Sequelae), Causal relationship (Very Probable, Probable, Possible, Unlikely, Not related, Not evaluable), Outcome of the AE (Recovered, Not Recovered, Recovered with sequelae, Death, Unknown), Attitude towards treatment of study (Continuation, Definitive interruption). Measurement time: At the end of treatment
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
19 years
Maximum age:
74 years
Inclusion criteria:
1. Adult with SARS-CoV2 infection diagnosed by RT-PCR. 2. Remain asymptomatic with SARS-CoV2 positive PCR for more than 30 days. 3. That the antibody kit tests do not detect antibodies. 4. That there is no history of anaphylaxis reactions with blood products. 5. That at the clinical evaluation by the attending physician there are no contraindications for plasma transfusion. 6. That the patient or their relatives give their informed consent to receive this donation.
Exclusion criteria:
None
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Observational
Purpose:
Treatment
Allocation:
N/A: single arm study
Masking:
Open
Control group:
Uncontrolled
Study design:
Single group
Phase:
N/A
Target sample size:
All patients who meet the criteria until September 30, 2020
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Consuelo
Last Name:
Macias Abraham
Specialty:
Specialist 2nd Degree in Immunology
Affiliation:
Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”
Postal Address:
Eighth Street No. 460, between 17 and 19, Vedado, Revolution Square
City:
Havana
Country:
Cuba
Zip Code:
10400
Telephone:
+53-78465555, +53-78465554
Email :
cmabraham@infomed.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Consuelo
Last Name:
Macias Abraham
Specialty:
Specialist 2nd Degree in Immunology
Affiliation:
Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”
Postal Address:
Eighth Street No. 460, between 17 and 19, Vedado, Revolution Square
City:
Havana
Country:
Cuba
Zip Code:
10400
Telephone:
+53-78465555, +53-78465554
Email :
cmabraham@infomed.sld.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
30/04/2020
Postal address of Ethic Committee :
Eighth Street No. 460, between 17 and 19, Vedado, Revolution Square, ZP: 10400, Havana, Cuba
Telephone:
+53-78461106
Email:
ensayosihi@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Final enrolment number:
22
Study completion date:
12/10/2020
Date of available results:
12/12/2020
Date of first publication:
12/03/2021
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000323
Date of Registration in Primary Registry:
03/07/2020
Record Verification Date:
2020/08/19
Next update date:
2021/08/19
Link to the spanish version:
Click here
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform